RE:RE:This is Much Bigger Than Barium This disclosure appears for the 1st time in the MD&A dated July 31, 2024. I missed it and probably so did many others because we assumed mgmt was just copy and pasting from one qtr to the next. It should have been disclosed in a news release as a material event.
Vertical Integration Strategy - a New Process to Make Iodine Drugs:
Voyageur has designed a proprietary streamlined iodine production system that creates vertical integration of all essential iodine-based compounds used in the creation of iodine contrast drugs. ICI is the starting compound for all iodine components including the intermediary compound 5-amino-2,4,6-triiodoisophthalic dichloride. The Voyageur streamlined method will eliminate the need to manufacture iodine flake and we will create both our ICl and 5-amino-2,4,6-triiodoisophthalic dichloride direct from the first stage ICl compound. This will result in the creation of our final API iodine crystal compound that is mixed with purified water in the final finished drug product.
Currently, the industry creates Iodine flake from the ICI, which is created to allow for transportation of dry iodine flake in barrel containers. Iodine flake is the main ingredient used by iodine drug companies and the iodine compound intermediary companies Our competitors purchase the flake and the 5-amino-2,4,6- triiodoisophthalic acid dichloride for a very high price. (I2 flake $70,000/tonne, 5-amino-2,4,6- triiodoisophthalic acid dichloride $95,000/tonne). They then put the I2 flake through an expensive process to reduce it back to its original form of ICl. ICl is then combined with 5-amino-2,4,6-triiodoisophthalic acid dichloride to create the final Iohexol/Iopamidol API crystal to be mixed with water for the final injectable drug.
Voyageurs new streamlined process eliminates the need for both the expensive intermediary compound and the flake, resulting in significant cost savings. Voyageur plans to be the first vertically integrated company globally and to become the only manufacturer of iodine drugs in North America. The results will provide supply chain security at lower costs for the global markets.